Profile picture

Professor Lars Kober

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)
Membership: FESC Member
Follow
Biography
Professor of Cardiology and Consultant, MD, D.Sci Graduated from University of Copenhagen and specialist in internal medicine and cardiology. Research interests: heart failure, coronary heart disease, atrial fibrillation and the cardiovascular consequences of comorbidities, with a focus on clinical trials and epidemiology. Main research activity is clinical trials and cardiovascular epidemiology. Serves as a member of the executive committee or steering committee in a number of large trials in heart failure and ischemic heart disease. The publication list encompasses more than 750 peer reviewed papers, and includes the 2015-2019 Highly Cited Researchers listing by Thomson Reuters.
Logo ESC

Contributor content

HFrEF treatment: where are we and where are we going?
Session
HFrEF treatment: where are we and where are we going?
29 August 2025
Session III: Management and Clinical Trials
Session
Session III: Management and Clinical Trials
9 October 2024
Distinct features of trials on non-pharmacological interventions and on special populations
Session
Distinct features of trials on non-pharmacological interventions and on special populations
21 September 2024
Clinical trial procedures
Session
Clinical trial procedures
20 September 2024
Smaller trials, trial updates, and other studies on heart failure (2)
Session
Smaller trials, trial updates, and other studies on heart failure (2)
31 August 2024
Metabolic markers in chronic coronary syndrome
Session
Metabolic markers in chronic coronary syndrome
28 August 2023
Current view of sudden cardiac death in heart failure
Session
Current view of sudden cardiac death in heart failure
22 May 2023
Chronic heart failure - Epidemiology, prognosis, outcome 1
Session
Chronic heart failure - Epidemiology, prognosis, outcome 1
28 August 2022
Controversies in primary prevention of sudden cardiac death in 2021: should Class I recommended for ICD be reconsidered?
Session
Controversies in primary prevention of sudden cardiac death in 2021: should Class I recommended for ICD be reconsidered?
30 June 2021
Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death
Session
Who should receive the wearable cardioverter defibrillator? Evidence and risk stratification for prevention of sudden cardiac death
26 May 2019

ESC 365 is supported by